Every Form 4 that Cyclerion Therapeutics, Inc. (CYCN) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow CYCN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CYCN filings page.
Cyclerion Therapeutics, Inc. (CYCN) reported that director Michelle Patricia Pernice received a grant of stock options covering 48,445 shares of common stock on September 9, 2026. The options have an exercise price of $26.20 per share, vest in equal monthly installments through September 9, 2029, and expire on September 9, 2036. Following this grant, she holds options on 48,445 shares directly, and no Rule 10b5-1 trading plan is reported.
Cyclerion Therapeutics, Inc. (CYCN) reported that director Nimish P. Shah received a grant of stock options on September 9, 2026 to acquire 48,445 shares of common stock at an exercise price of $26.20 per share. These options vest in equal monthly installments through September 9, 2029 and expire on September 9, 2036. According to an agreement with Venrock Management, LLC, the option and underlying shares are held for the sole benefit of Venrock Management, which is entitled to the underlying shares, and Shah disclaims beneficial ownership except to the extent of his pecuniary interest.
Cyclerion Therapeutics, Inc. (CYCN) reported that investment entities associated with Fairmount Funds Management LLC received a compensatory grant of stock options indirectly held through Tomas Kiselak. On September 9, 2026, an option for 48,445 shares of common stock was awarded at an exercise price of $26.20 per share, with no cash paid for the grant. The option vests in equal monthly installments through September 9, 2029, and expires on September 9, 2036. The filing states that Kiselak holds the option for one or more Fairmount-managed investment vehicles, and Fairmount, Peter Harwin, and Kiselak each disclaim beneficial ownership except to the extent of any pecuniary interest.
Cyclerion Therapeutics, Inc. (CYCN) reported that director Andrew Gottesdiener received a grant of stock options covering 48,445 shares of common stock on September 9, 2026. The options have an exercise price of $26.20 per share, expire on September 9, 2036, and vest in equal monthly installments through September 9, 2029, subject to his continued service.
Under an agreement with Venrock Management, LLC, the option and underlying shares are held for the sole benefit of Venrock Management, which is entitled to the underlying shares; Gottesdiener and Venrock Management each may be deemed indirect beneficial owners, and Gottesdiener disclaims beneficial ownership except to the extent of his pecuniary interest. No Rule 10b5-1 trading plan is reported.
Cyclerion Therapeutics, Inc. (CYCN) reported that its Chief Financial Officer, Rhonda M. Chicko, exercised stock options for 25,000 shares of common stock on August 14, 2026 at an exercise price of $2.355 per share, paid in cash. These options, granted on August 7, 2025 under the 2019 Equity Incentive Plan and originally vesting over time, had all remaining vesting accelerated by the board on July 17, 2026. After the exercise, Chicko directly holds 25,018 shares of common stock and no remaining options from this specific grant.
Cyclerion Therapeutics, Inc. reported that President and Chief Executive Officer Regina Margaret Graul exercised an employee stock option for 55,849 shares of common stock at $3.30 per share on August 14, 2026. The option, originally granted on August 5, 2024 under the 2019 Equity Incentive Plan, had its remaining unvested portion fully accelerated by the board on July 17, 2026. The exercise was completed as a cashless exercise, with options to purchase 48,629 shares forfeited to Cyclerion as payment of the full exercise price, and the reported option position reduced to zero following the transaction.
Cyclerion Therapeutics, Inc. director and 10% owner Peter M. Hecht converted 351,037 shares of Series A Convertible Preferred Stock into 351,037 shares of Common Stock on July 16, 2026, leaving no preferred shares outstanding. His direct Common Stock holdings after the conversion total 910,240 shares, and all previously held stock options were cancelled the same day. Separate family trusts each hold 24 Common shares, for which he disclaims beneficial ownership.